<DOC>
	<DOCNO>NCT01697787</DOCNO>
	<brief_summary>This two-arm study aim recruit 150 patient assess efficacy Amodiaquine-Artesunate ( ASAQ ) Artemether-Lumefantrine ( AL ) patient microscopy positive diagnosis malaria Nanoro , Burkina Faso assess performance Rapid Diagnosis Tests ( RDTs ) compare microscopy .</brief_summary>
	<brief_title>Amodiaquine-Artesunate &amp; Artemether-Lumefantrine Efficacy Burkina Faso</brief_title>
	<detailed_description>Study background purpose - Resistance usual drug widespread require change malaria treatment several country - Several country change first-line treatment ACTs ; mainly AL ASAQ . &amp; adopt use RDTs prior treatment - Indeed , contribute decrease number unnecessary treatment thus improve management malaria case . - In February 2005 , Burkina Faso change national drug policy Chloroquine Amodiaquine-Artesunate ( ASAQ ) Artemether-Lumefantrine ( AL ) - country also implement strategy use Rapid Diagnosis Tests ( RDTs ) diagnosis malaria prior treatment - Though endemic country encourage implement RDTs , choose particular RDT easy several brand available market . - In addition , little information performance RDTs Africa available recently quality problem report RDTs . - In context , important locally assess performance RDTs compare microscopy , gold standard malaria diagnosis ass efficacy new drug use malaria treatment This phase IV two-arm randomize open-label study aim recruit 150 patient assess efficacy ASAQ AL patient microscopy positive diagnosis malaria Nanoro , Burkina Faso assess performance RDT compare microscopy</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Amodiaquine</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<criteria>Age 6 month , eight 5 kg ; Positive blood slide ( parasitaemia ≥ 2,000/μL 200,000/μL ) Plasmodium falciparum monospecific infection ; Fever ( axillary temperature 37.5 °C ) history fever precede 24 hour ; Haemoglobin value equal 5.0 g/dL Signed informed consent ; Willingness ability comply study protocol duration trial . Participation investigational drug study ( antimalarial others ) previous 30 day Known hypersensitivity study drug Severe malaria Danger sign : able drink breastfeed , vomit ( &gt; twice 24hours ) , recent history convulsion ( 1 24h ) , unconscious state , unable sit stand ; Known intercurrent illness condition ( cardiac , renal , hepatic disease ) would place subject undue risk interfere result study . Severe malnutrition ( defined weight height le 70 % median NCHS/WHO reference ) Known pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Treatment , diagnosis</keyword>
</DOC>